Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

PD-L1 anticorps (C-Term)

Cet anticorps anti-PD-L1 est un anticorps Lapin Polyclonal détectant PD-L1 dans WB, FACS, IF, ICC, IHC (p) et IHC (fro). Adapté pour Humain. Ce Primary Antibody a été cité dans 7+ publications.
N° du produit ABIN2855940

Aperçu rapide pour PD-L1 anticorps (C-Term) (ABIN2855940)

Antigène

Voir toutes PD-L1 Anticorps
PD-L1 (CD274 (PD-L1))

Reactivité

  • 225
  • 146
  • 65
  • 6
  • 6
  • 5
  • 5
  • 1
  • 1
Humain

Hôte

  • 135
  • 106
  • 27
  • 5
  • 4
  • 4
  • 2
  • 1
Lapin

Clonalité

  • 160
  • 115
  • 7
Polyclonal

Conjugué

  • 117
  • 23
  • 17
  • 17
  • 13
  • 5
  • 5
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Cet anticorp PD-L1 est non-conjugé

Application

  • 166
  • 152
  • 66
  • 64
  • 40
  • 33
  • 28
  • 23
  • 21
  • 13
  • 11
  • 8
  • 7
  • 7
  • 6
  • 3
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunocytochemistry (ICC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Classe de qualité

KO Validated
  • Épitope

    • 31
    • 29
    • 16
    • 15
    • 9
    • 9
    • 7
    • 7
    • 7
    • 6
    • 4
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    C-Term

     Réactivité croisée

    Humain

    Attributs du produit

    Rabbit Polyclonal antibody to PD-L1 (CD274 Molecule)
    PD-L1 antibody

    Purification

    Purified by antigen-affinity chromatography.

    Immunogène

    Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human PD-L1. The exact sequence is proprietary.

    Isotype

    IgG
  • Indications d'application

    WB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.

    Commentaires

    Positive Control: MDA-MB-231 (24μg/ml Tunicamycin treatment for 16 hr) , MDA-MB-231 , A431(100 ng/mL IFN-gamma treatment for 48 hr)

    Validation: Comparison, KO/KD, Orthogonal, Overexpression

    Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    0.29 mg/mL

    Buffer

    1XPBS, 1 % BSA, 20 % Glycerol ( pH 7), 0.025 % ProClin 300

    Agent conservateur

    ProClin

    Précaution d'utilisation

    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Stock

    4 °C,-20 °C

    Stockage commentaire

    Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
  • Kim, Kim, Kim, Kim, Kim: "Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder." dans: Journal of clinical medicine, Vol. 9, Issue 5, (2020) (PubMed).

    Qin, Wang, Ye, Li, Chen, Wang, Qin, Zhang, Li, Long, Hu, Shi, Li, Zhang, Zhai, Tang, Kang, Lan, Xie, Lu, Deng: "NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer." dans: Nature communications, Vol. 11, Issue 1, pp. 1669, (2020) (PubMed).

    Gondhowiardjo, Handoko, Adham, Rachmadi, Kodrat, Tobing, Haryoga, Dwiyono, Kristian, Mayang Permata: "Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer." dans: PLoS ONE, Vol. 15, Issue 3, pp. e0230449, (2020) (PubMed).

    Pan, Wu, Kan, Li, Chang, Wu, Li, Ou-Yang, Hou, Yip, Luo: "Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer." dans: Cancers, Vol. 12, Issue 1, (2019) (PubMed).

    Cha, Yang, Xia, Wei, Chan, Lim, Li, Kim, Chang, Lee, Hsu, Wang, Kuo, Chang, Hadad, Purdie, McCoy, Cai, Tu, Litton, Mittendorf, Moulder, Symmans, Thompson, Piwnica-Worms, Chen, Khoo, Hung: "Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1." dans: Molecular cell, Vol. 71, Issue 4, pp. 606-620.e7, (2019) (PubMed).

    Buisseret, Garaud, de Wind, Van den Eynden, Boisson, Solinas, Gu-Trantien, Naveaux, Lodewyckx, Duvillier, Craciun, Veys, Larsimont, Piccart-Gebhart, Stagg, Sotiriou, Willard-Gallo: "Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer." dans: Oncoimmunology, Vol. 6, Issue 1, pp. e1257452, (2017) (PubMed).

    Lin, Sung, Hsieh, Tsai, Lai, Yang, Shen, Chen, Lee, Yeh, Chen: "High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma." dans: PLoS ONE, Vol. 10, Issue 11, pp. e0142656, (2016) (PubMed).

  • Antigène

    PD-L1 (CD274 (PD-L1))

    Autre désignation

    CD274 molecule

    Sujet

    Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.

    Cellular Localization: Isoform 1: Cell membrane, Single-pass type I membrane protein , Isoform 2: Endomembrane system, Single-pass type I membrane protein

    Poids moléculaire

    33 kDa

    ID gène

    29126

    UniProt

    Q9NZQ7

    Pathways

    Cancer Immune Checkpoints
Vous êtes ici:
Chat with us!